Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sclera
- Development stage
- Unknown
- Lead developer
- Hikma Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sclera (dimethyl fumarate) is a small molecule oral medication developed by Hikma Pharmaceuticals as a generic version of Tecfidera for the treatment of relapsing-remitting multiple sclerosis (RRMS). It is marketed under the brand names Sclera and Marovarex in the Middle East and North Africa (MENA) region. The drug is formulated as delayed-release gastro-resistant hard capsules in 120mg and 240mg strengths. Its mechanism of action involves the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) mediated antioxidative response pathway, which provides cytoprotective effects and modulates the immune response. Hikma has conducted observational studies to evaluate the real-world effectiveness, safety, and impact on quality of life for patients using this generic formulation in routine clinical practice.
- Brand names
- ScleraMarovarex
- Other names
- dimethyl fumarateDMF
02
Targets
NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)HCAR2 (Hydroxycarboxylic acid receptor 2)
Beyond the preview
Go deeper on Sclera.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sclera.